Drug Profile
Dacomitinib - Pfizer
Alternative Names: Dacomitinib; PF-00299804; PF-299; PF-299804; PF-804; VIZIMPROLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Pfizer
- Developer Fondazione IRCCS Istituto Nazionale dei Tumori; Memorial Sloan-Kettering Cancer Center; Netherlands Cancer Institute; Pfizer; Seoul National University Hospital; SFJ Pharmaceuticals; University Health Network; University of California, San Diego
- Class Amides; Aniline compounds; Antineoplastics; Piperidines; Quinazolinones; Small molecules
- Mechanism of Action Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists; ERBB 4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Non-small cell lung cancer
- Phase II Squamous cell cancer
- Discontinued Brain metastases; Gastric cancer; Glioblastoma; Head and neck cancer; Orofacial cancer; Solid tumours
Most Recent Events
- 28 Feb 2022 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (PO, Tablet)
- 27 Jan 2022 Pfizer completes the phase III ARCHER-1050 trial in Non-small cell lung caner (First-line therapy, Late-stage disease, Metastatic disease, Recurrent) in China, Hong Kong, Italy, Japan, South Korea, Spain and Poland (NCT01774721)
- 27 Jan 2021 Celcuity, Pfizer and Sarah Cannon Research Institute enter a clinical trial collaboration for a phase II trial for Breast cancer (PO)